Interestingly, several publications have proposed that irAEs might be related to significantly better ORR, PFS, and OS in NSCLC patients who received PD-1/PD-L1 inhibitor monotherapy [87, 98, 99]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.